Desloratadine as Adjunct Therapy for Rheumatoid Arthritis

Sponsor
Horus University
Study ID
NCT07632872
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

  • Desloratadine 5 mg — DRUG
    Desloratadine administered orally as add on therapy to standard disease modifying antirheumatic drugs.
  • Placebo — DRUG
    Matching placebo administered orally as add on therapy to standard disease modifying antirheumatic drugs.

Study Details

Rheumatoid arthritis is a chronic inflammatory disease that causes joint pain, swelling, and reduced physical function. Although standard disease-modifying antirheumatic drugs are effective for many patients, some individuals continue to have active disease. The purpose of this study is to evaluate the effectiveness and safety of adding desloratadine to standard therapy in patients with active rheumatoid arthritis. Participants will receive either desloratadine or placebo in addition to their usual treatment. The study will assess changes in disease activity and inflammatory markers over a follow-up period of approximately 12 weeks. The results of this study may help determine whether desloratadine could be a useful add-on treatment option for patients with rheumatoid arthritis.

Key Dates

First listed
Jun 8, 2026
Start date
May 23, 2026
Status verified
Jun 2026
Primary completion
Nov 30, 2026
Completion
Jan 31, 2027

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Desloratadine Group
    Participants will receive desloratadine 5mg in addition to standard disease modifying antirheumatic drug therapy.
  • Experimental: Placebo Group
    Participants will receive placebo in addition to standard disease modifying antirheumatic drug therapy.

Primary Outcome Measure

Change in Disease Activity Score (DAS28) [ Time Frame: 12 weeks ]

Central Contacts

Find similar trials

Nationwide
Rheumatoid arthritis trialsRheumatology trialsAutoimmune disease trialsMusculoskeletal disorders trials

Related Studies